TCAF ETF Analysis: T. Rowe Price Capital | NYSE

Large Blend | NYSE, USA | Market Cap: 7.880m USD | 12M Return: 12.1% | Charts, Fundamentals & Technical Analysis

Equity Securities, Large Cap Stocks, Technology Stocks, Healthcare Stocks
Total Rating 47
Safety 46
Buy Signal -0.28
Large Blend
Category Rotation: -1.2
TER: 0.31%
AUM: 7.88B
Avg Turnover: 22.0M
Risk 3d forecast
Volatility11.8%
VaR 5th Pctl2.23%
VaR vs Median4.73%
Reward TTM
Sharpe Ratio0.64
Rel. Str. IBD43.7
Rel. Str. Peer Group19.3
Character TTM
Beta0.882
Beta Downside0.879
Hurst Exponent0.571
Drawdowns 3y
Max DD16.37%
CAGR/Max DD1.01
CAGR/Mean DD8.04

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 3 years of data

Jan +0.3% 0
Feb -2.9% 35
Mar -5.9% 44
Apr +2.9% 0
May +2.9% 41
Jun +0.5% 11
Jul +0.9% 0
Aug -0.7% 30
Sep +0.4% 0
Oct -2.0% 29
Nov +0.8% 0
Dec -3.5% 37

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TCAF T. Rowe Price Capital

T. Rowe Price Capital Appreciation Equity ETF (TCAF) is a U.S.-listed, non-diversified ETF that invests at least 80% of its net assets in equity securities. The fund typically focuses on large-capitalization U.S. companies, although it is permitted to purchase stocks of any size.

Portfolio exposure may be concentrated in specific sectors, notably information technology and healthcare-two of the largest segments of the U.S. equity market, encompassing industries such as software, semiconductors, pharmaceuticals, and medical devices. Launched on June 14, 2023, TCAF is classified as a Large Blend fund.

Headlines to Watch Out For
  • Large cap US equities rally lifts portfolio NAV
  • Information technology sector concentration drives fund performance
  • T. Rowe Price ETF inflows expand AUM and fee revenue
What is the price of TCAF shares?

As of July 28, 2026, the stock is trading at USD 40.86 with a total of 452,295 shares traded. Over the past week, the price has changed by -0.56%, over one month by +0.10%, over three months by +3.89% and over the past year by +12.14%.

Current recommended Stop Loss: 40.30 (which is 1.4% or 1.5 ATR below the current price).

Is TCAF a buy, sell or hold?

T. Rowe Price Capital has no consensus analysts rating.